NEW YORK, July 20, 2026, 18:06 EDT
Shares of AtaiBeckley Inc. NASDAQ:ATAI finished Monday at $7.19, standing 44 cents above the cash bid from Eli Lilly and Co. NYSE:LLY. Reporting occurred after Nasdaq’s standard session had concluded.
The first undiscounted projection puts the contingent figure at $0.44, accounting for 17.6% of the total potential $2.50.
The trade is currently defined by that remaining value. The CVR will not be listed on any exchange. Its final milestone spans seven years after the deal closes.
The impact of the deal showed in trading on Monday. Shares of ATAI dropped 0.4%. The SPDR S&P Biotech ETF (NYSEARCA:XBI) lost 2.2%. Compass Pathways plc NASDAQ:CMPS fell 5.5%.
The previous week experienced a sharper increase. AtaiBeckley climbed by 39.7% for the week ending July 17, with Thursday alone witnessing a 33.4% gain.
Monday saw trading volumes decrease, with 22.3 million shares traded—a decline of about 87% from Thursday’s total of 166 million shares.
The offer splits the value into a cash payment and three additional milestone payments linked to clinical or regulatory achievements.
| Component | Per share | Trigger | Deadline after closing |
|---|---|---|---|
| Cash payout | $6.75 | Merger finalization | At closing; expected third quarter |
| VLS-01 milestone | $1.00 | Beginning of Phase 3 trial | Up to four years |
| BPL-003 milestone | $0.50 | U.S. approval along with DEA rescheduling | Up to five years |
| VLS-01 milestone | $1.00 | U.S. approval along with DEA rescheduling | Up to seven years |
The merger filing submitted on July 16 sets forth these deadlines. The CVR may be transferred only in limited situations. Both shareholder approval and antitrust clearance are required for the merger to move forward.
The direct $0.44 estimate is below the minimum $0.50 benchmark. This figure also factors in closure risk and extended periods of uncertainty tied to clinical developments.
The cash element stands 6.1% below Monday’s closing value before applying any discount. Total payment would reach $9.25, a 28.7% premium.
On Monday, analysts moved closer to that threshold. H.C. Wainwright’s Patrick Trucchio cut ATAI’s rating to Neutral and set the price target at $7.50. Berenberg similarly downgraded the stock to Hold, assigning a $7.45 price target.
Srinivas Rao, Chief Executive at AtaiBeckley, said Lilly’s “expertise and reach are expected to accelerate that work.” The firms expect the transaction to close in the third quarter. PR Newswire
AtaiBeckley’s public calendar lists no events set for this week. Attention shifts to the proxy statement and required approvals.
Risks: Investors could reject the merger, or regulatory sign-off may face delays. The CVR may result in no payment and will not be listed on public markets.
